1. Field of the Invention
The present invention pertains generally to the field of medical devices, and more specifically to a photoacoustic system for in-situ characterization and differentiation of biological tissues and fluids during medical procedures and examinations. The invention may incorporate transcutaneous needles where differentiation provides real-time benefits to a health care provider such as, but not limited to, improved needle tip localization, trajectory alignment, targeting or selection of specific structures, or providing feedback before triggering the throw of a biopsy collection tool during a biopsy procedure.
2. Background
The following is a description of the background of core needle biopsies (CNBs) and regional anesthesia (RA) procedures, an example of which is peripheral nerve blocks (PNBs). It should be understood that the device and method of the present invention is not limited to CNBs and RA procedures, but is applicable to a range of transcutaneous needle procedures, such as amniocentesis and pericardial access, and that CNBs and PNBs are being discussed simply by way of example. It should also be understood that the device and method of the present invention is applicable, but not limited to cancer or ligamentous tissues, blood, fatty tissues, lymph, bone, and foreign bodies.
Cancer diagnosis has recently undergone a significant advancement through the use of biomarker profiling. This technique uses ribonucleic acid (RNA) sequencing of the tumor rather than a pathological examination and eliminates the subjective nature of morphology review. It also leads to more effective treatment regimens specifically chosen based on the tumor progenitor rather than the pathology. Additionally, biomarker profiling allows earlier detection and diagnosis and reduction in both false positive sampling rates and misdiagnosis.
Samples for biomarker profiling are collected through either diagnostic surgery or diagnostic needle biopsy. The former is undesirable due to the need for general anesthesia, inpatient care, and increased costs and complications. Diagnostic needle biopsies are performed through fine needle aspiration (FNA) or CNB. CNB provides a larger tissue sample block than FNA and is desirable when trying to extract the increased material volume necessary for biomarker profiling. The CNB procedure is generally performed by radiologists under the guidance of technologies such as but not limited to ultrasound imaging or computed tomography to determine when the needle has reached the targeted tumor mass.
Though these guidance methods have significantly improved successful biopsy rates, the effectiveness of tumor detection is still unacceptably low; the failure rate for acquiring adequate prostate tumor samples is 25-75%. This failure rate is due to limitations of the modalities to provide proper resolution and contrast during the CNB procedure. Examples include cases where a tumor does not have defined architecture and edges, a benign lesion mimics malignancy, or the anatomical site is difficult to access (e.g., the axillary region or prostate gland). Because there is no in situ confirmation of tumor prior to capture, issues such as registration misalignment between needle and image are only realized by inferior tissue samples identified during pathology. Therefore, to collect enough material, health care providers can take from 3-12 cores in more conventional procedures to 60-80 cores in a more comprehensive transperineal saturation biopsy technique.
Regional Anesthesia (RA) requires inserting a sharp cannula through delicate anatomy until the distal tip approaches the targeted neural structure. RA is divided into two main categories—Central, where the spinal nerves/cord are targeted and Peripheral, where a specific nerve bundle is targeted.
Central:
Epidural anesthesia requires inserting a needle (e.g., 17G (gauge)) through the tough ligament and muscle of the back and into the epidural space. After the distal tip reaches the epidural space, the catheter is threaded through the needle. The greatest risks from epidural needle insertion are puncturing the dural membrane and nerve injury, due to the tough ligamentum flavum that is just proximal to the epidural space (i.e., a potential space) and softer dura. Incorrect trajectory and bone contact can create more pain for the patient and increased time for the procedure. The challenge is to provide a method of tissue discrimination anterior to the needle for earlier identification of a) mis-trajectory and b) tissue type/thickness with minimal signal contamination from bony structures (vertebrae).
Peripheral:
Peripheral anesthesia requires inserting a needle (e.g., 18G) through the tissue layers, until the distal tip of the needle is close to the target nerve(s) or nervovascular bundle, without damaging the nerve by intra-neural injection. Peripheral anesthesia has shown an advantage over Central anesthesia due to decreased hospital length of stay and superior pain control with fewer side-effects. Ultrasound imaging is often used to guide the needle tip close to the nerve; however, precise in-plane needle tip localization within various tissue layers remains a challenge. Chronic pain management uses fluoroscopy to guide needle placement, exposing the patient and health care provider to harmful radiation.
Photoacoustic (PA) imaging is a fundamental shift in how tissue composition can be characterized. A short laser pulse is directed into biological tissue where the thermal absorption is highly dependent on the chemical composition of the tissue structures. Because the pulse is shorter than the thermal and elastic relaxation times of biological tissues, this absorption ultimately results in acoustic (ultrasound) generation that can be detected by a separate sensor. Sensing of tissue type and enhanced tissue contrast is superior compared to conventional ultrasound imaging because the modality is not based purely on mechanical properties of the tissue (i.e., density and sound velocity). High spatial resolution and sensitivity are possible because of the one-way (transmitter-to-tissue) light propagation, which provides less attenuation and scattering of light relative to purely optical (two-way propagation) techniques.
Typical PA systems use large, powerful, and costly Q-switched laser sources to create very high intensity beams which are then diverged to illuminate an area of tissue, often several square millimeters at the surface. This approach is used to ensure that an adequate fluence to produce detectable PA signals is achieved over the whole area. Fluence ranges have varied between investigators from approximately 1.4 mJ/cm2 to 20 mJ/cm2 (the clinical exposure threshold limit at short wavelengths). Resolution of the systems is based on the laser pulse width and resonance frequency of the ultrasound receiver. The Q-switched laser sources generally provide pulse widths of 5 ns to 10 ns. The ultrasound receivers in these systems are typically linear (phased) ultrasound array imaging systems that incorporate complex beamforming techniques to produce high-resolution, 2D images of the tissues from the PA signals.
By using an interrogation method that is essentially producing a 1D image, or line of data, more focused and lower intensity laser sources can be used. Laser diodes are less costly and require less electronics infrastructure than Q-switched laser sources. This not only allows sources producing multiple laser wavelengths to be housed in a single, practically sized system, but also reduces costs by an order of magnitude. By using an optical fiber with a diameter less than 200 μm (numerical aperture, 0.14-0.22), the illumination area is greatly decreased. Laser diodes of less than 500 mW can achieve a laser fluence of 3 mJ/cm2, which is sufficient to produce a PA response. This is in part due to the longer pulse time of diodes relative to other laser sources. This is at the expense of resolution, though research in the UK demonstrated that using laser diodes with pulse widths up to 500 ns could produce adequate PA images.
Multispectral Optoacoustic Imaging may be used for successful tumor interrogation with the present invention. Conventional multispectral imaging is a technique where many images are obtained at discrete wavelengths and then recombined into composite images to highlight and identify features through the resulting color patterns. This can highlight areas such as water, vegetation, or roads in satellite imagery or even different antibodies in mixed immunohistochemical staining. Multispectral photoacoustic imaging (MSPI) is similar in theory; each recorded “image” consists of the time-domain photoacoustic echo that results from discrete wavelength light (laser light) illuminating the structures. Researchers that have so far used MSPI for biological imaging have mainly relied on tunable lasers (laser/oscillator combinations) to provide spectral bandwidth of up to 2200 nm. Using this bandwidth, the lasers have matched multiple absorption peaks of lipids, collagen, and hemoglobin to distinguish plaques, tumors, muscle, and bony structures. Though these are highly flexible systems, the laser sources are large, costly and the wavelength scan speeds are tens of nanometers per second much too slow for real-time imaging with MSPI over an 800 nm bandwidth.
Various features of the invention will be set forth in part in the following description, or may be obvious from the description, or may be learned from practice of the invention. It is hereby noted that the term “in vivo” is defined as performing an act or process within a living organism or natural setting. For example, performing the act of prostate tissue photoacoustic characterization in vivo refers to illuminating prostate tissue in a living being, human or other, while it is in place and still performing all natural physiological functions.
The device herein may be used in a range of tissue types in vivo in a human or animal. The device may be in some aspects of some exemplary embodiments a control box coupled to a reusable handpiece and a disposable needle system that work together to identify biological tissues and fluids distal to the disposable needle during procedures that include needle insertions into the body. Some embodiments may differentiate healthy and cancer cells in situ. These embodiments may allow repositioning of a needle during biopsies prior to tissue capture to maximize the amount of tissue sample collected. Yet other embodiments may differentiate between tissue types, muscle, spaces (e.g., epidural space), and vessels. This will provide the health care provider with feedback in real-time to allow needle repositioning, improve needle localization and decrease the likelihood of over-insertion. The system may be used in conjunction with a conventional ultrasound imaging system for needle visualization, a method that is currently considered standard protocol for many procedures that involve needle insertions.
The disposable needle system may in some exemplary embodiments consist of both a cannula and stylet with integration of an optical fiber into the stylet to deliver light pulses through the stylet and out of the distal end—allowing materials directly in front of the needle to be illuminated. The cannula and stylet may be separable from one another in some procedures to allow injection or aspiration through the cannula after placement in the body. Integration of the disposable needle system with the reusable handpiece may require the use of custom connections.
The control box may house one or more light sources each of which are capable of very short time duration pulses of light. These pulses of light may provide a short burst of energy that is large enough to produce a photoacoustic effect and short enough to not produce any damage in tissues, biological fluids, or other structures. The use of multiple wavelengths of light provides the ability to distinguish the biological materials based on a multispectral approach, whereby each material exhibits a unique pattern of acoustic signals based on the interaction and absorption of light with the chemical structure of the illuminated materials.
A method is also disclosed in other aspects of other exemplary embodiments for the in vivo photoacoustic distinction of biological tissues or fluids during a needle insertion procedure within a living being. The method may include coupling a first end of a disposable needle system incorporating a fiber optic member to a handpiece where the handpiece remains outside of the living being. A second end of the disposable needle system may be placed through the skin of the living being into sub-dermal tissues. The method may also involve coupling the handpiece to an illumination mechanism where the illumination mechanism produces light output at multiple distinct wavelengths, and energizing the illumination mechanism such that the disposable needle system receives light at the first end and transfers the light out of the second end of the disposable needle system in a distal direction. The light exiting the second end of the disposable needle system may pass into the biological tissues or fluids of the living being to interact in such a way as to produce an acoustic response from the biological tissues or fluids. Further, an acoustic receiver may be positioned on the surface of the living being and interact with proximal-traveling acoustic pressure waves and convert the acoustic pressure waves into voltage or charge signals. The method may also include coupling the acoustic receiver to a receiver mechanism where the receiver mechanism samples the voltage or charge signals and also remains outside of the living being, and binning the sampled amplitudes of the voltage or charge signals from the receiver mechanism for each distinct wavelength at each time point or set of time points. Additionally, the method may involve using an algorithm to compare the combination of all sampled amplitudes at each time point or set of time points with combinations of amplitudes of known biological materials or other materials, producing a prediction of what biological material or other material the unknown materials are at each time point or set of time points, and converting each predicted biological material or other material to a distinct representative color. The method may involve relaying the resultant color line representing the biological materials or other materials as a function of time or distance to a display monitor, and the display monitor may remain outside of the living being.
These and other features and aspects of the present invention will become better understood with reference to the following description and appended claims. The accompanying drawings, which are incorporated in and constitute part of this specification, illustrate embodiments of the invention and, together with the description, serve to explain the principles of the invention.
A full and enabling disclosure of the present invention, including the best mode thereof, directed to one of ordinary skill in the art, is set forth more particularly in the remainder of the specification, which makes reference to the appended Figs. in which:
Repeat use of reference characters in the present specification and drawings is intended to represent the same or analogous features or elements of the invention.
Reference will now be made in detail to embodiments of the invention, one or more examples of which are illustrated in the drawings. Each example is provided by way of explanation of the invention, and not meant as a limitation of the invention. For example, features illustrated or described as part of one embodiment can be used with another embodiment to yield still a third embodiment. It is intended that the present invention include these and other modifications and variations.
It is to be understood that the ranges mentioned herein include all ranges located within the prescribed range. As such, all ranges mentioned herein include all sub-ranges included in the mentioned ranges. For instance, a range from 100-200 also includes ranges from 110-150, 170-190, and 153-162.
The present photoacoustic needle insertion devices and methods may provide a means to differentiate biological tissues and fluids, such as but not limited to muscle, fat, bone, nerves, deoxygenated or oxygenated blood, and tumorous or necrosed tissue, directly along the projected trajectory of a needle or similar lancing device during medical diagnostic or treatment procedures or examinations using needles, preferably a regional anesthesia, biopsy or vascular access procedure. Implementing the light pulses into a needle system may require, in some instances, the use of custom connections. Certain preferred embodiments are illustrated in
As used herein, the distal direction is the direction toward the patient and away from the health care provider. The proximal direction is toward the health care provider and away from the patient. Illustrations used herein are specific to four laser sources but the number of laser diode sources, and therefore the number of interrogation wavelengths, could be reduced or increased with modification in accordance with various exemplary embodiments.
The output laser beams 2a-2d may or may not be collimated, or have minimal diffraction, due to focusing. The output laser beams 2a-2d from the laser diodes 4a-4d are directed through a series of dichroic mirrors 3 that are reflective or transmissive to specific light wavelengths such that all of the output laser beams 2a-2d form a single coaxial output laser beam 49 that enters a fiber optic coupler 6, such as a focused aspheric lens, after passing through a controllable optical shutter 11 that is used to block any output for safety during non-use. The laser diodes 4a-4d are controlled by a short wavelength driver 9a, medium wavelength driver 9b, long wavelength driver 9c, and extra-long wavelength driver 9d that create pulses of electrical current at least equal in magnitude to the emission threshold current but less than 110% of the maximum operating current of the laser diodes 4a-4d. The time durations of the electrical current pulses, as defined by the full width at half maximum time duration, are between 1 nanoseconds (ns) and 500 ns, but preferentially between 30 ns and 150 ns. During each pulse cycle, each laser diode 4a-4d is driven by a single electrical current pulse by the respective laser diode driver 9a-9d. The time delay between single electrical current pulses to the laser diodes 4a-4d, such as the time delay between pulsing laser diode 4a with laser diode driver 9a and pulsing laser diode 4b with laser diode driver 9b, are between 1 microsecond and 400 microseconds, but preferentially between 10 microseconds and 100 microseconds. The time duration of the pulse cycle is between 5 microseconds and 10 milliseconds (ms), but preferentially between 250 microseconds and 2 ms. The display monitor 25 communicates with the electronics sub-system 20 through a wireless protocol and wireless transmitter 51, and is powered by batteries. In a less preferential embodiment, the display monitor 25 is physically connected to the control box 1 and communicates with the electronics sub-system 20 through a hardwired connection.
As will be discussed in detail later, there are two types of needle insertion systems disclosed herein for example but this invention is not limited to only these two types of needle insertion systems. Both examples use the in-needle photoacoustic interrogation principle to exemplify the inventions. Both approaches may use a control box and receiver system. Both approaches may apply light pulses and record acoustic signals transmitted from within the patient or subject.
While the present invention has been described in connection with certain preferred embodiments, it is to be understood that the subject matter encompassed by way of the present invention is not to be limited to those specific embodiments. On the contrary, it is intended for the subject matter of the invention to include all alternatives, modifications and equivalents as can be included within the spirit and scope of the following claims.
This patent application claims the benefit of U.S. Patent Application Ser. No. 61/931,286, filed Jan. 24, 2014 entitled Photoacoustic Needle Insertion Platform. U.S. Patent Application Ser. No. 61/931,286 is incorporated by reference herein in its entirety for all purposes.
This invention was produced in part using funds from the Federal government under National Institutes of Health Contract Award ID No. HHSN261201400015C. Accordingly, the government has certain rights in the invention.
Number | Date | Country | |
---|---|---|---|
61931286 | Jan 2014 | US |